1-Boc-3-(甲苯-4-磺酰氧基)-哌啶 | 85275-46-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-Boc-3-(甲苯-4-磺酰氧基)-哌啶
• 中文别名: 3-(对甲苯磺酰氧基)哌啶-1-甲酸叔丁酯
• 英文名称: tert-butyl 3-(tosyloxy)piperidine-1-carboxylate
• 英文别名: 3-(toluene-4-sulfonyloxy)-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 3-(4-methylphenyl)sulfonyloxypiperidine-1-carboxylate
• CAS: 85275-46-3
• 化学式: C₁₇H₂₅NO₅S
• mdl: MFCD07787194
• 分子量: 355.455
• InChiKey: SKOKKOPKFKENHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.588
• 拓扑面积：
  81.3
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: t-Butyl 3-(p-tolylsulfonyloxy)piperidine-1-carboxylate
tert-Butyl 3-{[(4-methylbenzene)sulfonyl]oxy}piperidine-1-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: t-Butyl 3-(p-tolylsulfonyloxy)piperidine-1-carboxylate
CAS number: 85275-46-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H25NO5S
Molecular weight: 355.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-Boc-3-(甲苯-4-磺酰氧基)-哌啶 在 4-二甲氨基吡啶 、 caesium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 50.0h， 生成 tert-butyl 3-(5-(tert-butoxycarbonylamino)-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE
  [FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON

  摘要：

  该发明提供了由化学式（IV）表示的新型多取代的5-成员杂环化合物，或其药学上可接受的盐、溶剂化合物、代谢物、多形体、酯、互变异构体或前药，以及包含这些化合物的组合物。所提供的化合物可用作选择性不可逆的布鲁顿酪氨酸激酶（Btk）抑制剂，并且进一步用于治疗与异常B细胞增殖相关的炎症、自身免疫疾病，如类风湿关节炎（RA）和癌症。该发明还提供了利用化学式（IV）制备药物的方法，以及预防或治疗与哺乳动物，尤其是人类中Btk活性过高相关的疾病的方法。 化学式（IV）

  公开号：

  WO2014082598A1
• 作为产物：
  描述：

  N-BOC-3-羟基哌啶 、 对甲苯磺酰氯 在 氮气 、 乙酸乙酯 、 盐酸 、 碳酸氢钠 、 Brine 、 Sodium sulfate-III 作用下， 以 吡啶 为溶剂， 反应 48.0h， 以to afford 1.1 g (60%) of tert-butyl 3-(tosyloxy)piperidine-1-carboxylate as a colorless oil的产率得到1-Boc-3-(甲苯-4-磺酰氧基)-哌啶
  参考文献：
  名称：

  Protein Kinase Inhibitors and Uses Thereof

  摘要：

  本发明涉及公式（I）的化合物及其盐，组合物和使用方法。特别地，本文披露了某些化合物，可以用于抑制蛋白激酶，包括布鲁顿酪氨酸激酶（Btk），并用于治疗由此介导的疾病。

  公开号：

  US20150005277A1

文献信息

• [EN] BENZOSULFONYL COMPOUNDS<br/>[FR] COMPOSÉS DE BENZOSULFONYLE
  申请人：VIVACE THERAPEUTICS INC

  公开号：WO2019040380A1

  公开（公告）日：2019-02-28

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

  本文提供了包含所述化合物的用于治疗癌症的药物组合物。具体的癌症包括那些由YAP/TAZ介导或由YAP/TAZ与TEAD相互作用调节的癌症。
• BTK INHIBITOR
  申请人：Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

  公开号：US20170313683A1

  公开（公告）日：2017-11-02

  Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

  提供了一系列的BTK抑制剂，特别公开了一种由公式(I)、(II)、(III)或(IV)表示的化合物、药用可接受的盐、互变异构体或前药。
• 一种1,3-二取代吲唑类化合物及其制备方法和应用
  申请人：山东大学

  公开号：CN112110908A

  公开（公告）日：2020-12-22

  本发明公开了一种1,3‑二取代吲唑类化合物及其制备方法和应用，化学结构如式Ⅰ所示：其中，X、Y为两个连接基团，X选自苄基、哌啶基、吡咯基、哌嗪基、吗啉基；Y选自苄基、哌啶基、哌嗪基、吗啉基、吡咯烷基、苯胺基、氮；Z、Z’均选自氢、卤素、硝基、氨基、取代氨基、氰基、甲基、丁酰基、环丙甲酰基、甲氧甲酰基、甲氧基、三氟甲基、甲磺酰基、甲硫基。本发明提供的化合物具有一定的HIF‑1抑制活性，可用于抗肿瘤药物的制备。本发明的实验数据表明，部分化合物对HIF‑1α表现出较强的抑制活性。另外，本发明对套细胞淋巴瘤细胞和肝癌细胞的生长抑制作用也较强。
• [EN] PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLYLE PYRIMIDINE ET LEUR UTILISATION COMME INHIBITEURS D'IRAK
  申请人：MERCK PATENT GMBH

  公开号：WO2015106058A1

  公开（公告）日：2015-07-16

  The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.

  本发明提供了用于治疗癌症、类风湿性关节炎和其他疾病的化合物（II）的公式。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014135495A1

  公开（公告）日：2014-09-12

  The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

  本发明公开了化合物的结构式I：其中结构式I中的变量如本文所述。还公开了含有这些化合物的药物组合物，以及使用结构式I中的化合物预防或治疗HCV感染的方法。